Masahiko Shimura
7PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Jun 11, 2025
Factors that contribute to loss to follow-up in the medium term after initiation of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in Japanese patients.Takaaki Sugisawa, Fumi Gomi, Yuri Harada
|Apr 10, 2025
Efficacy of Aflibercept (8 mg) for Diabetic Macular Edema in Vitrectomized Eyes Refractory to the Other Anti-VEGF Drug Therapies: A Report of Three Cases.Ikumi Kashiwagi, Ryota Nonaka, Shotaro Sasaki
|Oct 18, 2024
ALTERATION OF TREATMENT CHOICES AND THE VISUAL PROGNOSIS FOR DIABETIC MACULAR EDEMA IN THE ERA OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR DRUGS: Analysis of the STREAT-DME 2 Study.Masahiko Shimura, Takao Hirano, Eiko Tsuiki
|Jul 31, 2024
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trial.Masahiko Shimura, Hideyasu Oh, Tetsuo Ueda
|Mar 10, 2023
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.Masahiko Shimura, Shigehiko Kitano, Nahoko Ogata
|Mar 15, 2020
Real-world management of treatment-naïve diabetic macular oedema: 2-year visual outcome focusing on the starting year of intervention from STREAT-DMO study.Masahiko Shimura, Shigehiko Kitano, Daisuke Muramatsu
Pageof 2
